Immunovant, Inc.
Immunovant, Inc. (Nasdaq: IMVT) is a clinical-stage immunology company developing antibody medicines for autoimmune diseases driven by pathogenic immunoglobulin G (IgG). Its lead candidate, IMVT-1402 (imeroprubart), is a fully human monoclonal antibody that inhibits the neonatal fragment crystallizable receptor… From the company’s description.
In fiscal 2025, Immunovant, Inc. reported a net loss of $505.61M. Operations used $407.31M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Immunovant, Inc. does
In the company’s own words
Immunovant, Inc. (Nasdaq: IMVT) is a clinical-stage immunology company developing antibody medicines for autoimmune diseases driven by pathogenic immunoglobulin G (IgG). Its lead candidate, IMVT-1402 (imeroprubart), is a fully human monoclonal antibody that inhibits the neonatal fragment crystallizable receptor (FcRn), with the aim of reducing IgG antibodies; the company is studying it in Graves’ disease, difficult-to-treat rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, Sjögren’s disease and cutaneous lupus erythematosus. The programs address potential treatment needs in endocrinology, rheumatology, neurology and dermatology, serving patients with autoimmune conditions. Immunovant also developed batoclimab, its first-generation FcRn inhibitor, but discontinued its development in 2026 to focus on IMVT-1402. Its research and development programs are organized by therapeutic area, and the company relies on third parties for manufacturing and clinical-trial activities. Immunovant reported no product revenue and had no marketed products as of fiscal 2026. Its website is www.immunovant.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- DURHAM, NC
- Fiscal year end
- March
- CIK
- 1764013
- SIC
- 2836
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Immunovant, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Immunovant, Inc. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Immunovant, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Immunovant, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Immunovant, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Immunovant, Inc.'s last four quarterly filings that the numbers alone won't show?”